graph Evidence gap map comparisons
anti-PD-(L)1durvalumab based treatmentsintilimab based treatmentImmune checkpoint associationnivolumab plus ipilimumab
cemiplimab durvalumab alone sintillimab plus SoC durvalumab plus tremelimumab nivolumab plus ipilimumab plus SoC
mNSCLC - L1 - all population 5           
Comparator:  vs Standard of Care (SoC);   vs placebo plus SoC; 
Risk of bias:  low;   some concerns;   high;  NA;